Emerging Company Profile
Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer
Emerging Company Profile: Myeloid launches with programmed monocyte cell therapies for cancer
Myeloid launches with over $50 million from lead investor Newpath and monocyte cell therapies engineered to target cancer cells and coordinate antitumor immune functions.
Jan 8, 2021 | 2:46 AM GMT
Myeloid is engineering monocytes as cellular cancer therapies by programming pluripotent myeloid cells to target tumor